Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435224 | 1.00 | NAMPT (0.37) | NAMPTDGAT1NPC1RAB9AKDM4E | |
| SCHEMBL2431677 | 0.92 | KDM4E (0.36) | NAMPTDGAT1NPC1RAB9AKDM4E | |
| SCHEMBL2431675 | 0.92 | KDM4E (0.36) | NAMPTDGAT1NPC1RAB9AKDM4E | |
| SCHEMBL2435757 | 0.87 | NPC1 (0.45) | NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2435755 | 0.87 | NPC1 (0.45) | NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2432594 | 0.86 | KMT2A (0.39) | NAMPTDGAT1 | |
| SCHEMBL2432592 | 0.86 | KMT2A (0.39) | NAMPTDGAT1 | |
| SCHEMBL13630805 | 0.86 | DGAT1 (0.34) | NAMPTDGAT1NPC1RAB9AKDM4E | |
| SCHEMBL2432516 | 0.86 | KMT2A (0.41) | DGAT1NPC1RAB9AKDM4E | |
| SCHEMBL2432524 | 0.86 | KMT2A (0.41) | DGAT1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | NAMPT 3959/4885DGAT1 4164/4885NPC1 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.